Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Medicure (MCUJF) Asset Writedowns and Impairment (2019 - 2020)

Medicure has reported Asset Writedowns and Impairment over the past 6 years, most recently at $284577.3 for Q4 2020.

For Q4 2020, Asset Writedowns and Impairment fell 93.46% year-over-year to $284577.3; the TTM value through Dec 2020 reached $513982.7, down 86.16%, while the annual FY2023 figure was $205303.1, 633.36% up from the prior year.
Asset Writedowns and Impairment for Q4 2020 was $284577.3 at Medicure, up from $75005.2 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $4.4 million in Q4 2019 and troughed at $75005.2 in Q2 2020.